Global Neurodegenerative Diseases Therapeutics Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Description

According to our (Global Info Research) latest study, the global Neurodegenerative Diseases Therapeutics market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

This report is a detailed and comprehensive analysis for global Neurodegenerative Diseases Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:
Global Neurodegenerative Diseases Therapeutics market size and forecasts, in consumption value ($ Million), 2018-2029
Global Neurodegenerative Diseases Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Neurodegenerative Diseases Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Neurodegenerative Diseases Therapeutics market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Neurodegenerative Diseases Therapeutics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Neurodegenerative Diseases Therapeutics market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AB Science SA, AbbVie Inc., Acadia Pharmaceuticals Inc., Biogen Inc. and F. Hoffmann La Roche Ltd., etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation
Neurodegenerative Diseases Therapeutics market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    Multiple Sclerosis Therapeutics
    Alzheimer's Disease Therapeutics
    Parkinson's Disease Therapeutics
    Parkinson's Disease Therapeutics
    Others

Market segment by Application
    Child
    Aldult

Market segment by players, this report covers
    AB Science SA
    AbbVie Inc.
    Acadia Pharmaceuticals Inc.
    Biogen Inc.
    F. Hoffmann La Roche Ltd.
    H Lundbeck AS
    Mitsubishi Chemical Holdings Corp.
    Novartis AG
    Sanofi
    Teva Pharmaceutical Industries Ltd

Market segment by regions, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
    South America (Brazil, Argentina and Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Neurodegenerative Diseases Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Neurodegenerative Diseases Therapeutics, with revenue, gross margin and global market share of Neurodegenerative Diseases Therapeutics from 2018 to 2023.
Chapter 3, the Neurodegenerative Diseases Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Neurodegenerative Diseases Therapeutics market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Neurodegenerative Diseases Therapeutics.
Chapter 13, to describe Neurodegenerative Diseases Therapeutics research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Neurodegenerative Diseases Therapeutics
    1.2 Market Estimation Caveats and Base Year
    1.3 Classification of Neurodegenerative Diseases Therapeutics by Type
        1.3.1 Overview: Global Neurodegenerative Diseases Therapeutics Market Size by Type: 2018 Versus 2022 Versus 2029
        1.3.2 Global Neurodegenerative Diseases Therapeutics Consumption Value Market Share by Type in 2022
        1.3.3 Multiple Sclerosis Therapeutics
        1.3.4 Alzheimer's Disease Therapeutics
        1.3.5 Parkinson's Disease Therapeutics
        1.3.6 Parkinson's Disease Therapeutics
        1.3.7 Others
    1.4 Global Neurodegenerative Diseases Therapeutics Market by Application
        1.4.1 Overview: Global Neurodegenerative Diseases Therapeutics Market Size by Application: 2018 Versus 2022 Versus 2029
        1.4.2 Child
        1.4.3 Aldult
    1.5 Global Neurodegenerative Diseases Therapeutics Market Size & Forecast
    1.6 Global Neurodegenerative Diseases Therapeutics Market Size and Forecast by Region
        1.6.1 Global Neurodegenerative Diseases Therapeutics Market Size by Region: 2018 VS 2022 VS 2029
        1.6.2 Global Neurodegenerative Diseases Therapeutics Market Size by Region, (2018-2029)
        1.6.3 North America Neurodegenerative Diseases Therapeutics Market Size and Prospect (2018-2029)
        1.6.4 Europe Neurodegenerative Diseases Therapeutics Market Size and Prospect (2018-2029)
        1.6.5 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size and Prospect (2018-2029)
        1.6.6 South America Neurodegenerative Diseases Therapeutics Market Size and Prospect (2018-2029)
        1.6.7 Middle East and Africa Neurodegenerative Diseases Therapeutics Market Size and Prospect (2018-2029)

2 Company Profiles
    2.1 AB Science SA
        2.1.1 AB Science SA Details
        2.1.2 AB Science SA Major Business
        2.1.3 AB Science SA Neurodegenerative Diseases Therapeutics Product and Solutions
        2.1.4 AB Science SA Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
        2.1.5 AB Science SA Recent Developments and Future Plans
    2.2 AbbVie Inc.
        2.2.1 AbbVie Inc. Details
        2.2.2 AbbVie Inc. Major Business
        2.2.3 AbbVie Inc. Neurodegenerative Diseases Therapeutics Product and Solutions
        2.2.4 AbbVie Inc. Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
        2.2.5 AbbVie Inc. Recent Developments and Future Plans
    2.3 Acadia Pharmaceuticals Inc.
        2.3.1 Acadia Pharmaceuticals Inc. Details
        2.3.2 Acadia Pharmaceuticals Inc. Major Business
        2.3.3 Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Product and Solutions
        2.3.4 Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
        2.3.5 Acadia Pharmaceuticals Inc. Recent Developments and Future Plans
    2.4 Biogen Inc.
        2.4.1 Biogen Inc. Details
        2.4.2 Biogen Inc. Major Business
        2.4.3 Biogen Inc. Neurodegenerative Diseases Therapeutics Product and Solutions
        2.4.4 Biogen Inc. Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
        2.4.5 Biogen Inc. Recent Developments and Future Plans
    2.5 F. Hoffmann La Roche Ltd.
        2.5.1 F. Hoffmann La Roche Ltd. Details
        2.5.2 F. Hoffmann La Roche Ltd. Major Business
        2.5.3 F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Product and Solutions
        2.5.4 F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
        2.5.5 F. Hoffmann La Roche Ltd. Recent Developments and Future Plans
    2.6 H Lundbeck AS
        2.6.1 H Lundbeck AS Details
        2.6.2 H Lundbeck AS Major Business
        2.6.3 H Lundbeck AS Neurodegenerative Diseases Therapeutics Product and Solutions
        2.6.4 H Lundbeck AS Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
        2.6.5 H Lundbeck AS Recent Developments and Future Plans
    2.7 Mitsubishi Chemical Holdings Corp.
        2.7.1 Mitsubishi Chemical Holdings Corp. Details
        2.7.2 Mitsubishi Chemical Holdings Corp. Major Business
        2.7.3 Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Product and Solutions
        2.7.4 Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
        2.7.5 Mitsubishi Chemical Holdings Corp. Recent Developments and Future Plans
    2.8 Novartis AG
        2.8.1 Novartis AG Details
        2.8.2 Novartis AG Major Business
        2.8.3 Novartis AG Neurodegenerative Diseases Therapeutics Product and Solutions
        2.8.4 Novartis AG Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
        2.8.5 Novartis AG Recent Developments and Future Plans
    2.9 Sanofi
        2.9.1 Sanofi Details
        2.9.2 Sanofi Major Business
        2.9.3 Sanofi Neurodegenerative Diseases Therapeutics Product and Solutions
        2.9.4 Sanofi Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
        2.9.5 Sanofi Recent Developments and Future Plans
    2.10 Teva Pharmaceutical Industries Ltd
        2.10.1 Teva Pharmaceutical Industries Ltd Details
        2.10.2 Teva Pharmaceutical Industries Ltd Major Business
        2.10.3 Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Product and Solutions
        2.10.4 Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Revenue, Gross Margin and Market Share (2018-2023)
        2.10.5 Teva Pharmaceutical Industries Ltd Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Neurodegenerative Diseases Therapeutics Revenue and Share by Players (2018-2023)
    3.2 Market Share Analysis (2022)
        3.2.1 Market Share of Neurodegenerative Diseases Therapeutics by Company Revenue
        3.2.2 Top 3 Neurodegenerative Diseases Therapeutics Players Market Share in 2022
        3.2.3 Top 6 Neurodegenerative Diseases Therapeutics Players Market Share in 2022
    3.3 Neurodegenerative Diseases Therapeutics Market: Overall Company Footprint Analysis
        3.3.1 Neurodegenerative Diseases Therapeutics Market: Region Footprint
        3.3.2 Neurodegenerative Diseases Therapeutics Market: Company Product Type Footprint
        3.3.3 Neurodegenerative Diseases Therapeutics Market: Company Product Application Footprint
    3.4 New Market Entrants and Barriers to Market Entry
    3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
    4.1 Global Neurodegenerative Diseases Therapeutics Consumption Value and Market Share by Type (2018-2023)
    4.2 Global Neurodegenerative Diseases Therapeutics Market Forecast by Type (2024-2029)

5 Market Size Segment by Application
    5.1 Global Neurodegenerative Diseases Therapeutics Consumption Value Market Share by Application (2018-2023)
    5.2 Global Neurodegenerative Diseases Therapeutics Market Forecast by Application (2024-2029)

6 North America
    6.1 North America Neurodegenerative Diseases Therapeutics Consumption Value by Type (2018-2029)
    6.2 North America Neurodegenerative Diseases Therapeutics Consumption Value by Application (2018-2029)
    6.3 North America Neurodegenerative Diseases Therapeutics Market Size by Country
        6.3.1 North America Neurodegenerative Diseases Therapeutics Consumption Value by Country (2018-2029)
        6.3.2 United States Neurodegenerative Diseases Therapeutics Market Size and Forecast (2018-2029)
        6.3.3 Canada Neurodegenerative Diseases Therapeutics Market Size and Forecast (2018-2029)
        6.3.4 Mexico Neurodegenerative Diseases Therapeutics Market Size and Forecast (2018-2029)

7 Europe
    7.1 Europe Neurodegenerative Diseases Therapeutics Consumption Value by Type (2018-2029)
    7.2 Europe Neurodegenerative Diseases Therapeutics Consumption Value by Application (2018-2029)
    7.3 Europe Neurodegenerative Diseases Therapeutics Market Size by Country
        7.3.1 Europe Neurodegenerative Diseases Therapeutics Consumption Value by Country (2018-2029)
        7.3.2 Germany Neurodegenerative Diseases Therapeutics Market Size and Forecast (2018-2029)
        7.3.3 France Neurodegenerative Diseases Therapeutics Market Size and Forecast (2018-2029)
        7.3.4 United Kingdom Neurodegenerative Diseases Therapeutics Market Size and Forecast (2018-2029)
        7.3.5 Russia Neurodegenerative Diseases Therapeutics Market Size and Forecast (2018-2029)
        7.3.6 Italy Neurodegenerative Diseases Therapeutics Market Size and Forecast (2018-2029)

8 Asia-Pacific
    8.1 Asia-Pacific Neurodegenerative Diseases Therapeutics Consumption Value by Type (2018-2029)
    8.2 Asia-Pacific Neurodegenerative Diseases Therapeutics Consumption Value by Application (2018-2029)
    8.3 Asia-Pacific Neurodegenerative Diseases Therapeutics Market Size by Region
        8.3.1 Asia-Pacific Neurodegenerative Diseases Therapeutics Consumption Value by Region (2018-2029)
        8.3.2 China Neurodegenerative Diseases Therapeutics Market Size and Forecast (2018-2029)
        8.3.3 Japan Neurodegenerative Diseases Therapeutics Market Size and Forecast (2018-2029)
        8.3.4 South Korea Neurodegenerative Diseases Therapeutics Market Size and Forecast (2018-2029)
        8.3.5 India Neurodegenerative Diseases Therapeutics Market Size and Forecast (2018-2029)
        8.3.6 Southeast Asia Neurodegenerative Diseases Therapeutics Market Size and Forecast (2018-2029)
        8.3.7 Australia Neurodegenerative Diseases Therapeutics Market Size and Forecast (2018-2029)

9 South America
    9.1 South America Neurodegenerative Diseases Therapeutics Consumption Value by Type (2018-2029)
    9.2 South America Neurodegenerative Diseases Therapeutics Consumption Value by Application (2018-2029)
    9.3 South America Neurodegenerative Diseases Therapeutics Market Size by Country
        9.3.1 South America Neurodegenerative Diseases Therapeutics Consumption Value by Country (2018-2029)
        9.3.2 Brazil Neurodegenerative Diseases Therapeutics Market Size and Forecast (2018-2029)
        9.3.3 Argentina Neurodegenerative Diseases Therapeutics Market Size and Forecast (2018-2029)

10 Middle East & Africa
    10.1 Middle East & Africa Neurodegenerative Diseases Therapeutics Consumption Value by Type (2018-2029)
    10.2 Middle East & Africa Neurodegenerative Diseases Therapeutics Consumption Value by Application (2018-2029)
    10.3 Middle East & Africa Neurodegenerative Diseases Therapeutics Market Size by Country
        10.3.1 Middle East & Africa Neurodegenerative Diseases Therapeutics Consumption Value by Country (2018-2029)
        10.3.2 Turkey Neurodegenerative Diseases Therapeutics Market Size and Forecast (2018-2029)
        10.3.3 Saudi Arabia Neurodegenerative Diseases Therapeutics Market Size and Forecast (2018-2029)
        10.3.4 UAE Neurodegenerative Diseases Therapeutics Market Size and Forecast (2018-2029)

11 Market Dynamics
    11.1 Neurodegenerative Diseases Therapeutics Market Drivers
    11.2 Neurodegenerative Diseases Therapeutics Market Restraints
    11.3 Neurodegenerative Diseases Therapeutics Trends Analysis
    11.4 Porters Five Forces Analysis
        11.4.1 Threat of New Entrants
        11.4.2 Bargaining Power of Suppliers
        11.4.3 Bargaining Power of Buyers
        11.4.4 Threat of Substitutes
        11.4.5 Competitive Rivalry
    11.5 Influence of COVID-19 and Russia-Ukraine War
        11.5.1 Influence of COVID-19
        11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis
    12.1 Neurodegenerative Diseases Therapeutics Industry Chain
    12.2 Neurodegenerative Diseases Therapeutics Upstream Analysis
    12.3 Neurodegenerative Diseases Therapeutics Midstream Analysis
    12.4 Neurodegenerative Diseases Therapeutics Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology
    14.2 Research Process and Data Source
    14.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Neurodegenerative Diseases Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Table 2. Global Neurodegenerative Diseases Therapeutics Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
    Table 3. Global Neurodegenerative Diseases Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
    Table 4. Global Neurodegenerative Diseases Therapeutics Consumption Value by Region (2024-2029) & (USD Million)
    Table 5. AB Science SA Company Information, Head Office, and Major Competitors
    Table 6. AB Science SA Major Business
    Table 7. AB Science SA Neurodegenerative Diseases Therapeutics Product and Solutions
    Table 8. AB Science SA Neurodegenerative Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 9. AB Science SA Recent Developments and Future Plans
    Table 10. AbbVie Inc. Company Information, Head Office, and Major Competitors
    Table 11. AbbVie Inc. Major Business
    Table 12. AbbVie Inc. Neurodegenerative Diseases Therapeutics Product and Solutions
    Table 13. AbbVie Inc. Neurodegenerative Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 14. AbbVie Inc. Recent Developments and Future Plans
    Table 15. Acadia Pharmaceuticals Inc. Company Information, Head Office, and Major Competitors
    Table 16. Acadia Pharmaceuticals Inc. Major Business
    Table 17. Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Product and Solutions
    Table 18. Acadia Pharmaceuticals Inc. Neurodegenerative Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 19. Acadia Pharmaceuticals Inc. Recent Developments and Future Plans
    Table 20. Biogen Inc. Company Information, Head Office, and Major Competitors
    Table 21. Biogen Inc. Major Business
    Table 22. Biogen Inc. Neurodegenerative Diseases Therapeutics Product and Solutions
    Table 23. Biogen Inc. Neurodegenerative Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 24. Biogen Inc. Recent Developments and Future Plans
    Table 25. F. Hoffmann La Roche Ltd. Company Information, Head Office, and Major Competitors
    Table 26. F. Hoffmann La Roche Ltd. Major Business
    Table 27. F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Product and Solutions
    Table 28. F. Hoffmann La Roche Ltd. Neurodegenerative Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 29. F. Hoffmann La Roche Ltd. Recent Developments and Future Plans
    Table 30. H Lundbeck AS Company Information, Head Office, and Major Competitors
    Table 31. H Lundbeck AS Major Business
    Table 32. H Lundbeck AS Neurodegenerative Diseases Therapeutics Product and Solutions
    Table 33. H Lundbeck AS Neurodegenerative Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 34. H Lundbeck AS Recent Developments and Future Plans
    Table 35. Mitsubishi Chemical Holdings Corp. Company Information, Head Office, and Major Competitors
    Table 36. Mitsubishi Chemical Holdings Corp. Major Business
    Table 37. Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Product and Solutions
    Table 38. Mitsubishi Chemical Holdings Corp. Neurodegenerative Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 39. Mitsubishi Chemical Holdings Corp. Recent Developments and Future Plans
    Table 40. Novartis AG Company Information, Head Office, and Major Competitors
    Table 41. Novartis AG Major Business
    Table 42. Novartis AG Neurodegenerative Diseases Therapeutics Product and Solutions
    Table 43. Novartis AG Neurodegenerative Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 44. Novartis AG Recent Developments and Future Plans
    Table 45. Sanofi Company Information, Head Office, and Major Competitors
    Table 46. Sanofi Major Business
    Table 47. Sanofi Neurodegenerative Diseases Therapeutics Product and Solutions
    Table 48. Sanofi Neurodegenerative Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 49. Sanofi Recent Developments and Future Plans
    Table 50. Teva Pharmaceutical Industries Ltd Company Information, Head Office, and Major Competitors
    Table 51. Teva Pharmaceutical Industries Ltd Major Business
    Table 52. Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Product and Solutions
    Table 53. Teva Pharmaceutical Industries Ltd Neurodegenerative Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 54. Teva Pharmaceutical Industries Ltd Recent Developments and Future Plans
    Table 55. Global Neurodegenerative Diseases Therapeutics Revenue (USD Million) by Players (2018-2023)
    Table 56. Global Neurodegenerative Diseases Therapeutics Revenue Share by Players (2018-2023)
    Table 57. Breakdown of Neurodegenerative Diseases Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3)
    Table 58. Market Position of Players in Neurodegenerative Diseases Therapeutics, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
    Table 59. Head Office of Key Neurodegenerative Diseases Therapeutics Players
    Table 60. Neurodegenerative Diseases Therapeutics Market: Company Product Type Footprint
    Table 61. Neurodegenerative Diseases Therapeutics Market: Company Product Application Footprint
    Table 62. Neurodegenerative Diseases Therapeutics New Market Entrants and Barriers to Market Entry
    Table 63. Neurodegenerative Diseases Therapeutics Mergers, Acquisition, Agreements, and Collaborations
    Table 64. Global Neurodegenerative Diseases Therapeutics Consumption Value (USD Million) by Type (2018-2023)
    Table 65. Global Neurodegenerative Diseases Therapeutics Consumption Value Share by Type (2018-2023)
    Table 66. Global Neurodegenerative Diseases Therapeutics Consumption Value Forecast by Type (2024-2029)
    Table 67. Global Neurodegenerative Diseases Therapeutics Consumption Value by Application (2018-2023)
    Table 68. Global Neurodegenerative Diseases Therapeutics Consumption Value Forecast by Application (2024-2029)
    Table 69. North America Neurodegenerative Diseases Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
    Table 70. North America Neurodegenerative Diseases Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
    Table 71. North America Neurodegenerative Diseases Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
    Table 72. North America Neurodegenerative Diseases Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
    Table 73. North America Neurodegenerative Diseases Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
    Table 74. North America Neurodegenerative Diseases Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
    Table 75. Europe Neurodegenerative Diseases Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
    Table 76. Europe Neurodegenerative Diseases Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
    Table 77. Europe Neurodegenerative Diseases Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
    Table 78. Europe Neurodegenerative Diseases Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
    Table 79. Europe Neurodegenerative Diseases Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
    Table 80. Europe Neurodegenerative Diseases Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
    Table 81. Asia-Pacific Neurodegenerative Diseases Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
    Table 82. Asia-Pacific Neurodegenerative Diseases Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
    Table 83. Asia-Pacific Neurodegenerative Diseases Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
    Table 84. Asia-Pacific Neurodegenerative Diseases Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
    Table 85. Asia-Pacific Neurodegenerative Diseases Therapeutics Consumption Value by Region (2018-2023) & (USD Million)
    Table 86. Asia-Pacific Neurodegenerative Diseases Therapeutics Consumption Value by Region (2024-2029) & (USD Million)
    Table 87. South America Neurodegenerative Diseases Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
    Table 88. South America Neurodegenerative Diseases Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
    Table 89. South America Neurodegenerative Diseases Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
    Table 90. South America Neurodegenerative Diseases Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
    Table 91. South America Neurodegenerative Diseases Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
    Table 92. South America Neurodegenerative Diseases Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
    Table 93. Middle East & Africa Neurodegenerative Diseases Therapeutics Consumption Value by Type (2018-2023) & (USD Million)
    Table 94. Middle East & Africa Neurodegenerative Diseases Therapeutics Consumption Value by Type (2024-2029) & (USD Million)
    Table 95. Middle East & Africa Neurodegenerative Diseases Therapeutics Consumption Value by Application (2018-2023) & (USD Million)
    Table 96. Middle East & Africa Neurodegenerative Diseases Therapeutics Consumption Value by Application (2024-2029) & (USD Million)
    Table 97. Middle East & Africa Neurodegenerative Diseases Therapeutics Consumption Value by Country (2018-2023) & (USD Million)
    Table 98. Middle East & Africa Neurodegenerative Diseases Therapeutics Consumption Value by Country (2024-2029) & (USD Million)
    Table 99. Neurodegenerative Diseases Therapeutics Raw Material
    Table 100. Key Suppliers of Neurodegenerative Diseases Therapeutics Raw Materials
List of Figures
    Figure 1. Neurodegenerative Diseases Therapeutics Picture
    Figure 2. Global Neurodegenerative Diseases Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 3. Global Neurodegenerative Diseases Therapeutics Consumption Value Market Share by Type in 2022
    Figure 4. Multiple Sclerosis Therapeutics
    Figure 5. Alzheimer's Disease Therapeutics
    Figure 6. Parkinson's Disease Therapeutics
    Figure 7. Parkinson's Disease Therapeutics
    Figure 8. Others
    Figure 9. Global Neurodegenerative Diseases Therapeutics Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 10. Neurodegenerative Diseases Therapeutics Consumption Value Market Share by Application in 2022
    Figure 11. Child Picture
    Figure 12. Aldult Picture
    Figure 13. Global Neurodegenerative Diseases Therapeutics Consumption Value, (USD Million): 2018 & 2022 & 2029
    Figure 14. Global Neurodegenerative Diseases Therapeutics Consumption Value and Forecast (2018-2029) & (USD Million)
    Figure 15. Global Market Neurodegenerative Diseases Therapeutics Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
    Figure 16. Global Neurodegenerative Diseases Therapeutics Consumption Value Market Share by Region (2018-2029)
    Figure 17. Global Neurodegenerative Diseases Therapeutics Consumption Value Market Share by Region in 2022
    Figure 18. North America Neurodegenerative Diseases Therapeutics Consumption Value (2018-2029) & (USD Million)
    Figure 19. Europe Neurodegenerative Diseases Therapeutics Consumption Value (2018-2029) & (USD Million)
    Figure 20. Asia-Pacific Neurodegenerative Diseases Therapeutics Consumption Value (2018-2029) & (USD Million)
    Figure 21. South America Neurodegenerative Diseases Therapeutics Consumption Value (2018-2029) & (USD Million)
    Figure 22. Middle East and Africa Neurodegenerative Diseases Therapeutics Consumption Value (2018-2029) & (USD Million)
    Figure 23. Global Neurodegenerative Diseases Therapeutics Revenue Share by Players in 2022
    Figure 24. Neurodegenerative Diseases Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
    Figure 25. Global Top 3 Players Neurodegenerative Diseases Therapeutics Market Share in 2022
    Figure 26. Global Top 6 Players Neurodegenerative Diseases Therapeutics Market Share in 2022
    Figure 27. Global Neurodegenerative Diseases Therapeutics Consumption Value Share by Type (2018-2023)
    Figure 28. Global Neurodegenerative Diseases Therapeutics Market Share Forecast by Type (2024-2029)
    Figure 29. Global Neurodegenerative Diseases Therapeutics Consumption Value Share by Application (2018-2023)
    Figure 30. Global Neurodegenerative Diseases Therapeutics Market Share Forecast by Application (2024-2029)
    Figure 31. North America Neurodegenerative Diseases Therapeutics Consumption Value Market Share by Type (2018-2029)
    Figure 32. North America Neurodegenerative Diseases Therapeutics Consumption Value Market Share by Application (2018-2029)
    Figure 33. North America Neurodegenerative Diseases Therapeutics Consumption Value Market Share by Country (2018-2029)
    Figure 34. United States Neurodegenerative Diseases Therapeutics Consumption Value (2018-2029) & (USD Million)
    Figure 35. Canada Neurodegenerative Diseases Therapeutics Consumption Value (2018-2029) & (USD Million)
    Figure 36. Mexico Neurodegenerative Diseases Therapeutics Consumption Value (2018-2029) & (USD Million)
    Figure 37. Europe Neurodegenerative Diseases Therapeutics Consumption Value Market Share by Type (2018-2029)
    Figure 38. Europe Neurodegenerative Diseases Therapeutics Consumption Value Market Share by Application (2018-2029)
    Figure 39. Europe Neurodegenerative Diseases Therapeutics Consumption Value Market Share by Country (2018-2029)
    Figure 40. Germany Neurodegenerative Diseases Therapeutics Consumption Value (2018-2029) & (USD Million)
    Figure 41. France Neurodegenerative Diseases Therapeutics Consumption Value (2018-2029) & (USD Million)
    Figure 42. United Kingdom Neurodegenerative Diseases Therapeutics Consumption Value (2018-2029) & (USD Million)
    Figure 43. Russia Neurodegenerative Diseases Therapeutics Consumption Value (2018-2029) & (USD Million)
    Figure 44. Italy Neurodegenerative Diseases Therapeutics Consumption Value (2018-2029) & (USD Million)
    Figure 45. Asia-Pacific Neurodegenerative Diseases Therapeutics Consumption Value Market Share by Type (2018-2029)
    Figure 46. Asia-Pacific Neurodegenerative Diseases Therapeutics Consumption Value Market Share by Application (2018-2029)
    Figure 47. Asia-Pacific Neurodegenerative Diseases Therapeutics Consumption Value Market Share by Region (2018-2029)
    Figure 48. China Neurodegenerative Diseases Therapeutics Consumption Value (2018-2029) & (USD Million)
    Figure 49. Japan Neurodegenerative Diseases Therapeutics Consumption Value (2018-2029) & (USD Million)
    Figure 50. South Korea Neurodegenerative Diseases Therapeutics Consumption Value (2018-2029) & (USD Million)
    Figure 51. India Neurodegenerative Diseases Therapeutics Consumption Value (2018-2029) & (USD Million)
    Figure 52. Southeast Asia Neurodegenerative Diseases Therapeutics Consumption Value (2018-2029) & (USD Million)
    Figure 53. Australia Neurodegenerative Diseases Therapeutics Consumption Value (2018-2029) & (USD Million)
    Figure 54. South America Neurodegenerative Diseases Therapeutics Consumption Value Market Share by Type (2018-2029)
    Figure 55. South America Neurodegenerative Diseases Therapeutics Consumption Value Market Share by Application (2018-2029)
    Figure 56. South America Neurodegenerative Diseases Therapeutics Consumption Value Market Share by Country (2018-2029)
    Figure 57. Brazil Neurodegenerative Diseases Therapeutics Consumption Value (2018-2029) & (USD Million)
    Figure 58. Argentina Neurodegenerative Diseases Therapeutics Consumption Value (2018-2029) & (USD Million)
    Figure 59. Middle East and Africa Neurodegenerative Diseases Therapeutics Consumption Value Market Share by Type (2018-2029)
    Figure 60. Middle East and Africa Neurodegenerative Diseases Therapeutics Consumption Value Market Share by Application (2018-2029)
    Figure 61. Middle East and Africa Neurodegenerative Diseases Therapeutics Consumption Value Market Share by Country (2018-2029)
    Figure 62. Turkey Neurodegenerative Diseases Therapeutics Consumption Value (2018-2029) & (USD Million)
    Figure 63. Saudi Arabia Neurodegenerative Diseases Therapeutics Consumption Value (2018-2029) & (USD Million)
    Figure 64. UAE Neurodegenerative Diseases Therapeutics Consumption Value (2018-2029) & (USD Million)
    Figure 65. Neurodegenerative Diseases Therapeutics Market Drivers
    Figure 66. Neurodegenerative Diseases Therapeutics Market Restraints
    Figure 67. Neurodegenerative Diseases Therapeutics Market Trends
    Figure 68. Porters Five Forces Analysis
    Figure 69. Manufacturing Cost Structure Analysis of Neurodegenerative Diseases Therapeutics in 2022
    Figure 70. Manufacturing Process Analysis of Neurodegenerative Diseases Therapeutics
    Figure 71. Neurodegenerative Diseases Therapeutics Industrial Chain
    Figure 72. Methodology
    Figure 73. Research Process and Data Source